Subtopic Deep Dive
Enzyme replacement therapy for hypophosphatasia
Research Guide
What is Enzyme replacement therapy for hypophosphatasia?
Enzyme replacement therapy (ERT) for hypophosphatasia uses asfotase alfa to replace deficient tissue-nonspecific alkaline phosphatase (TNSALP) activity, improving skeletal mineralization, survival, and motor function in patients.
Clinical trials demonstrate asfotase alfa's efficacy in perinatal and infantile hypophosphatasia, with survival rates improving from 28% to 84% at 12 months (Whyte et al., 2015, 258 citations). Long-term studies confirm sustained benefits in children, adolescents, and adults over five years (Whyte et al., 2016, 164 citations; Kishnani et al., 2018, 141 citations). Approximately 20 papers from 2012-2019 detail pharmacokinetics, immunogenicity, and monitoring protocols.
Why It Matters
Asfotase alfa, approved as the first ERT for hypophosphatasia, transforms outcomes in severe cases by mineralizing skeletons and enhancing respiratory function (Whyte et al., 2015). It reduces substrate accumulation like pyridoxal 5'-phosphate, addressing TNSALP deficiency (Kishnani et al., 2018). Monitoring guidance optimizes dosing and detects hypercalcemia risks (Kishnani et al., 2017), enabling pediatric use despite diagnostic delays (Högler et al., 2019).
Key Research Challenges
Immunogenicity to asfotase alfa
Antibody formation against asfotase alfa reduces efficacy in some patients, requiring immunogenicity monitoring (Whyte et al., 2016). Long-term studies track neutralizing antibodies impacting pharmacokinetics (Kishnani et al., 2018).
Optimizing dosing regimens
Variable pharmacokinetics in hypophosphatasia necessitate tailored dosing for mineralization and survival benefits (Whyte et al., 2015). Monitoring protocols address substrate accumulation and hypercalcemia (Kishnani et al., 2017).
Diagnostic and treatment delays
Delays in hypophosphatasia diagnosis hinder timely ERT initiation, worsening outcomes (Högler et al., 2019). Early intervention with asfotase alfa improves motor function but requires better screening (Whyte, 2017).
Essential Papers
Alkaline Phosphatase and Hypophosphatasia
José Luís Millán, Michael P. Whyte · 2015 · Calcified Tissue International · 367 citations
Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia
Michael P. Whyte, Cheryl R. Greenberg, Keiichi Ozono et al. · 2015 · The Journal of Clinical Endocrinology & Metabolism · 258 citations
Asfotase alfa mineralizes the HPP skeleton, including the ribs, and improves respiratory function and survival in life-threatening perinatal and infantile HPP.
Mechanism of Bone Mineralization
Monzur Murshed · 2018 · Cold Spring Harbor Perspectives in Medicine · 253 citations
Mineralized "hard" tissues of the skeleton possess unique biomechanical properties to support the body weight and movement and act as a source of essential minerals required for critical body funct...
Asfotase alfa therapy for children with hypophosphatasia
Michael P. Whyte, Katherine L. Madson, Dawn Phillips et al. · 2016 · JCI Insight · 164 citations
<b>Background.</b> Hypophosphatasia (HPP) is caused by loss-of-function mutation(s) of the gene that encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP). Consequently, cell-su...
Alkaline Phosphatase, an Unconventional Immune Protein
Bethany A. Rader · 2017 · Frontiers in Immunology · 153 citations
Recent years have seen an increase in the number of studies focusing on alkaline phosphatases (APs), revealing an expanding complexity of function of these enzymes. Of the four human AP (hAP) prote...
Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia
Priya S. Kishnani, Cheryl R. Greenberg, Frank Rauch et al. · 2018 · Bone · 141 citations
Hypophosphatasia (HPP) features low tissue-nonspecific alkaline phosphatase (TNSALP) isoenzyme activity resulting in extracellular accumulation of its substrates including pyridoxal 5'-phosphate (P...
Hypophosphatasia: Enzyme Replacement Therapy Brings New Opportunities and New Challenges
Michael P. Whyte · 2017 · Journal of Bone and Mineral Research · 140 citations
ABSTRACT Hypophosphatasia (HPP) is caused by loss-of-function mutation(s) of the gene that encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP). Autosomal inheritance (dominant...
Reading Guide
Foundational Papers
Start with Millán and Whyte (2015, 367 citations) for HPP pathophysiology, then Whyte et al. (2012) for initial asfotase alfa outcomes establishing ERT feasibility.
Recent Advances
Study Whyte et al. (2016, 164 citations) for pediatric efficacy and Kishnani et al. (2018, 141 citations) for long-term adult data; Högler et al. (2019) addresses diagnostic registries.
Core Methods
ERT trials use Kaplan-Meier survival analysis, BSID-III motor scales, radiographic global scores, and plasma PLP/pyridoxal measurements for TNSALP activity (Whyte et al., 2015; Kishnani et al., 2017).
How PapersFlow Helps You Research Enzyme replacement therapy for hypophosphatasia
Discover & Search
Research Agent uses searchPapers('asfotase alfa hypophosphatasia survival') to find Whyte et al. (2015, 258 citations), then citationGraph reveals 50+ citing papers on ERT outcomes; exaSearch uncovers global registry data like Högler et al. (2019); findSimilarPapers links to Kishnani et al. (2018) for long-term safety.
Analyze & Verify
Analysis Agent applies readPaperContent on Whyte et al. (2015) to extract survival data (28% untreated vs. 84% treated), verifies with verifyResponse (CoVe) against raw abstracts, and runPythonAnalysis plots Kaplan-Meier curves from extracted stats using matplotlib; GRADE grading scores high for randomized trial evidence in pediatric cohorts.
Synthesize & Write
Synthesis Agent detects gaps in adolescent ERT immunogenicity via contradiction flagging across Whyte et al. (2016) and Kishnani et al. (2018); Writing Agent uses latexEditText for protocol sections, latexSyncCitations for 20+ refs, latexCompile for full review, and exportMermaid diagrams mineralization pathways.
Use Cases
"Plot survival curves from asfotase alfa trials in infantile hypophosphatasia"
Research Agent → searchPapers → Analysis Agent → readPaperContent(Whyte 2015) → runPythonAnalysis (pandas/matplotlib Kaplan-Meier plot) → researcher gets publication-ready survival graph PNG.
"Draft LaTeX review on asfotase alfa monitoring in pediatric HPP"
Synthesis Agent → gap detection → Writing Agent → latexEditText(draft) → latexSyncCitations(15 papers) → latexCompile → researcher gets compiled PDF with figures and synced refs.
"Find code for TNSALP enzyme kinetics modeling from HPP papers"
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets runnable Python sims of mineralization from Millán-linked repos.
Automated Workflows
Deep Research workflow scans 50+ asfotase alfa papers via searchPapers → citationGraph → structured report on survival/mineralization; DeepScan's 7-step chain verifies Whyte et al. (2015) claims with CoVe checkpoints and Python stats; Theorizer generates hypotheses on immunogenicity from Whyte (2017) and Kishnani (2018).
Frequently Asked Questions
What is enzyme replacement therapy for hypophosphatasia?
ERT uses asfotase alfa to supply exogenous TNSALP, hydrolyzing substrates like PLP and inorganic pyrophosphate to enable skeletal mineralization (Whyte et al., 2015).
What methods prove asfotase alfa efficacy?
Phase II trials measured survival, motor function via BSID-III scores, and radiographic healing; five-year extensions tracked sustained benefits (Whyte et al., 2016; Kishnani et al., 2018).
What are key papers on asfotase alfa?
Whyte et al. (2015, 258 citations) shows survival gains; Whyte et al. (2016, 164 citations) details pediatric outcomes; Kishnani et al. (2018, 141 citations) reports adult/adolescent safety.
What open problems remain in HPP ERT?
Immunogenicity reduces efficacy; diagnostic delays persist (Högler et al., 2019); hypercalcemia monitoring needs refinement (Kishnani et al., 2017).
Research Alkaline Phosphatase Research Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Enzyme replacement therapy for hypophosphatasia with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers